L-Dopa pharmacokinetic profile with effervescent Melevodopa/Carbidopa versus standard-release Levodopa/Carbidopa tablets in Parkinson's disease: A Randomised study

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Stocchi, Fabrizio ^a   Vacca, Laura ^a   Grassini, Paola ^a   Pawsey, Stephen ^b   Whale, Holly ^b   Marconi, Stefano ^c   Torti, Margherita ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b Vernalis (RandD) Ltd   (United Kingdom)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; LEVODOPA METHYL ESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG SAFETY; EFFERVESCENT TABLET; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HUMAN; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR PERFORMANCE; PARKINSON DISEASE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; STANDARD RELEASE TABLET; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84934964379     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/369465     Document Type: Article

References (27)

1. C.W. Olanow, Y. Agid, Y. Mizuno et al., "Levodopa in the treatment of Parkinsons disease: current controversies, " Movement Disorders, vol. 19, no. 9, pp. 997-1005, 2004.
2. C. D. Marsden and J. D. Parkes, "Success and problems of long term levodopa therapy in Parkinsons disease, " The Lancet, vol. 1, no. 8007, pp. 345-349, 1977.
3. E. Miyawaki, K. Lyons, R. Pahwa et al., "Motor complications of chronic levodopa therapy in Parkinsons disease, " Clinical Neuropharmacology, vol. 20, no. 6, pp. 523-530, 1997.
4. F. Stocchi, "Prevention and treatment of motor fluctuations, " Parkinsonism and Related Disorders, vol. 9, supplement 2, pp. S73-S81, 2003.
5. F. Stocchi, "The levodopa wearing-off phenomenon in Parkinsons disease: pharmacokinetic considerations, " Expert Opinion on Pharmacotherapy, vol. 7, no. 10, pp. 1399-1407, 2006.
6. J. G. Nutt, "On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics, " Annals of Neurology, vol. 22, no. 4, pp. 535-540, 1987.
7. E. Melamed, V. Bitton, and O. Zelig, "Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators, " Neurology, vol. 36, no. 1, pp. 100-103, 1986.
8. J. G. Nutt, W. R. Woodward, J. P. Hammerstad, J. H. Carter, and J. L. Anderson, "The on-off phenomenon in Parkinsons disease. Relation to levodopa absorption and transport, " The New England Journal of Medicine, vol. 310, no. 8, pp. 483-488, 1984.
9. M. Contin and P. Martinelli, "Pharmacokinetics of levodopa, " Journal of Neurology, vol. 257, supplement 2, pp. 253-261, 2010.
10. P. Chaná, C. Kuntsmann, M. Reyes-Parada, and P. Sáez-Briones, "Delayed early morning turn ON in response to a single dose of levodopa in advanced Parkinsons disease: Pharmacokinetics should be considered, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 12, pp. 1782-1783, 2004.
11. M. G. Cersosimo and E. E. Benarroch, "Neural control of the gastrointestinal tract: implications for Parkinson disease, " Movement Disorders, vol. 23, no. 8, pp. 1065-1075, 2008.
12. R. Djaldetti, J. Baron, I. Ziv, and E. Melamed, "Gastric emptying in Parkinsons disease: patients with and without response fluctuations, " Neurology, vol. 46, no. 4, pp. 1051-1054, 1996.
13. R. Kurlan, K. P. Rothfield, W. R. Woodward et al., "Erratic gastric emptying of levodopa may cause random fluctuations of parkinsonian mobility, " Neurology, vol. 38, no. 3, pp. 419-421, 1988.
14. D. Nyholm, "Pharmacokinetic optimisation in the treatment of Parkinsons disease: an update, " Clinical Pharmacokinetics, vol. 45, no. 2, pp. 109-136, 2006.
15. M. C. Kurth, J. W. Tetrud, I. Irwin, W. H. Lyness, and J. W. Langston, "Oral levodopa/carbidopa solution versus tablets in Parkinsons patients with severe fluctuations: a pilot study, " Neurology, vol. 43, no. 5, pp. 1036-1039, 1993.
16. F. Stocchi, S. Ruggieri, A. Carta, P. Jenner, and A. Agnoli, "Different therapeutic approaches in Parkinsons disease. Clinical, pharmacological and physiological aspects, " in Disorders of Movements, N. F. Quinn and P. G. Jenner, Eds., pp. 137-146, Academic Press, London, UK, 1989.
17. F. Stocchi, L. Fabbri, L. Vecsei, A. Krygowska-Wajs, P. A. Monici Preti, and S. A. Ruggieri, "Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease, " Clinical Neuropharmacology, vol. 30, no. 1, pp. 18-24, 2007.
18. I. Rondelli, D. Acerbi, F. Mariotti, and P. Ventura, "Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection, " Journal of Chromatography B: Biomedical Applications, vol. 653, no. 1, pp. 17-23, 1994.
19. S. Vickers, C. A. Duncan, S. D. White et al., "Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog and rat, " Drug Metabolism and Disposition, vol. 6, no. 6, pp. 640-646, 1978.
20. K. Sasahara, T. Nitanai, T. Habara, T. Morioka, and E. Nakajima, "Dosage form design for improvement of bioavailability of levodopa III: influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients, " Journal of Pharmaceutical Sciences, vol. 69, no. 12, pp. 1374-1378, 1980.
21. M. J. Steiger, F. Stocchi, L. Bramante, S. Ruggieri, and N. P. Quinn, "The clinical efficacy of single morning doses of levodopa methyl ester: Dispersible Madopar and Sinemet plus in Parkinson disease, " Clinical Neuropharmacology, vol. 15, no. 6, pp. 501-504, 1992.
22. F. Stocchi, L. Barbato, L. Bramante, A. Bonamartini, and S. Ruggieri, "The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo, " Functional Neurology, vol. 9, no. 5, pp. 259-264, 1994.
23. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, "Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinicopathological study of 100 cases, " Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181-184, 1992.
24. M. M. Hoehn and M. D. Yahr, "Parkinsonism: onset, progression and mortality, " Neurology, vol. 17, no. 5, pp. 427-442, 1967.
25. H. Heikkinen, A. Varhe, T. Laine et al., "Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose, " British Journal of Clinical Pharmacology, vol. 54, no. 4, pp. 363-371, 2002.
26. C. D. Marsden, "Parkinsons disease, " The Lancet, vol. 335, no. 8695, pp. 948-952, 1990.
27. F. Silva, "Effects of CHF 1512, a new combination of levodopa methylester and carbidopa, onmotor fluctuations in Parkinsons disease: results from a European study, " Movement Disorders, vol. 21, supplement 13, pp. S119-S120, 2006.